msk re PANC. Take a look at Tanox as an alternative.
They have an entry inhibitor that works much earlier than anything else. TNX-355 acts"up streamof any other candidate". It's a anti-CD4 antibody expected to enter Phase 3 Q1. Pfizer's maravioc is the only other entry inhibitor in Phase 3 and it targets CCR5 as do four other large biotechs versus CD-4.
Also TNX-355 requires only twice monthly injections versus Fuzeon's twice daily.Biggest neg I could find in "Bioltechnology" writeup was a watch for possible immunosuppresive response.
Market Data 
Markets 
AI
